BC Platforms

BC Platforms provides an AI-driven genomic data analysis and management platform that transforms fragmented real-world data into decision-ready evidence for clinical, regulatory, payer, medical, and commercial decisions across the drug development lifecycle. The company's platform suite includes BC Unify (AI-driven end-to-end data mastering platform for ingesting, harmonizing, transforming, and enriching multi-modal data), BC Catalyst (a prompt-based precision medicine platform for AI-powered cohort building, biomarker discovery, and population health insights), BC Image (AI-driven platform automating image extraction, de-identification, and processing), BC Mosaic (trusted research environments for clinical, genomic, and multi-omics studies with regulatory-compliant audit trails), and BC Data (a global real-world data network for research and innovation). The platform leverages a unique AI-enabled federated architecture that helps reduce development timelines, shorten time to value, and enable personalized therapies, with data meeting EHDS and GDPR+ standards. BC Platforms serves life sciences companies (advancing discovery, development, regulatory approval, and market access) and healthcare organizations (anonymizing, monetizing, and safeguarding health data). The company has access to 187M+ patients, 20+ FDA/EMA submissions, over 90% of patients outside the US, and 150+ global data partners, and has signed a Strategic Collaboration Agreement with AWS to scale secure AI-powered research environments. BC Platforms differentiates itself through its 25+ years of experience, its federated analytics approach enabling patient-level data access without data movement, and its comprehensive multi-modal data capabilities spanning clinical, EMR, multi-omics, and imaging data. Founded in 1997 and headquartered in Zurich, Switzerland, BC Platforms has raised approximately $47.1 million in a Series D round backed by Boston Millennia Partners, Jolt Capital, Debiopharm, Tesi, IQVIA, Europa, BioMedPartners, and VP Venture Partners.